Firebrick Pharma Limited (FRE.AX)
ASX · AUD · Healthcare · Drug Manufacturers - General
A$0.028 (-9.68%) as of
Key statistics
- Market cap
- 8.63M
- EPS (TTM)
- -0.0100
- Dividend yield
- 0.00%
- 52-week range
- 0.0240 – 0.0740
- Beta
- 0.89
- Revenue (TTM)
- 135.62k
- Profit margin
- 0.00%
- Volume
- 20.56k
About Firebrick Pharma Limited
Firebrick Pharma Limited develops and commercializes povidone-iodine (PVP-I) products under the Nasodine brand in Asia, North America, Europe, and internationally. It offers nasal and throat spray PVP-I products for the treatment of common cold. The company was incorporated in 2012 and is based in Melbourne, Australia.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Headquarters
- Melbourne, VIC, Australia
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.